The pharmaceutical industry may not have been an early adopter of open innovation (OI), yet it has made significant strides in using OI in recent years. According to research “most leading pharmaceutical companies build their R&D organizations on traditional OI processes in combination with external networks”. However, there is still a lot of unexplored potential for pharmaceutical companies to use public and private open innovation tools.
NineSigma has been privileged to work with leading pharmaceutical, biotech and medical device manufacturing companies, from the very beginning of their endeavours with open innovation. Our long experience proves that open innovation methods can be effectively applied along the whole value chain of drug discovery and development process.